SXL
AVEO

Summit X LLC’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Summit X LLC’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,930
Closed -$18K – 266
2019
Q4 		$18K Buy
2,930
+830
+40% +$6.11K 0.01% 231
2019
Q3 		$18K Hold
2,100
– – 0.01% 227
2019
Q2 		$14K Buy
2,100
+800
+62% +$6.85K 0.01% 233
2019
Q1 		$14K Buy
+1,300
New +$13.4K 0.01% 239

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
XSC
X-Square Capital Guaynabo, Puerto Rico $297M AUM 32.87% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Summit X LLC's AVEO Position: Q1 2020 in Review

Summit X LLC sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2020, closing a stake of 2,930 shares — an estimated $18K sold.

Summit X LLC first reported a position in AVEO in Q1 2019 and held it in 4 quarters. The position peaked at $18K in Q4 2019. 35 funds tracked by Wall St. Rank hold AVEO as of Q1 2020.

  • Summit X LLC reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Summit X LLC sold 2,930 AVEO Pharmaceuticals, Inc. shares in Q1 2020, an estimated $18K.
  • Summit X LLC first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2019 and held it in 4 quarters.
  • Summit X LLC's AVEO Pharmaceuticals, Inc. position peaked at $18K in Q4 2019.
  • 35 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2020.

Based on Summit X LLC's 13F filing for Q1 2020, filed 13 May 2020.